PF-Atlas › Drugs › WNT

WNT

Idiopathic Pulmonary Fibrosis · R-spondin 3 expands AEC2 stem cell pool via WNT pathway

Mechanism
R-spondin 3 expands AEC2 stem cell pool via WNT pathway
Development stage
Phase I IND
Evidence level
Level 3 (Phase I)
Developer
Entrega Bio / UCSF

Overview

RSPO3 expands AEC2 organoids. WNT3a pathway drives AEC2 self-renewal. First drug to target the stem cell directly.

Explore related

Treatment profileR-spondin 3 expands AEC2 stem cell pool via WNT pathwayAll trialsResearch
Medical disclaimer. This page summarizes research about WNT for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.